Emmaus Life Sciences Inc (EMMA)
0.10
-0.01
(-5.88%)
USD |
OTCM |
May 17, 15:50
Emmaus Life Sciences Revenue (Quarterly): 5.018M for Sept. 30, 2023
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2023 | 5.018M |
| June 30, 2023 | 10.76M |
| March 31, 2023 | 6.753M |
| December 31, 2022 | 5.93M |
| September 30, 2022 | 4.939M |
| June 30, 2022 | 4.287M |
| March 31, 2022 | 3.234M |
| December 31, 2021 | 3.02M |
| September 30, 2021 | 5.766M |
| June 30, 2021 | 6.489M |
| March 31, 2021 | 5.335M |
| December 31, 2020 | 6.252M |
| September 30, 2020 | 5.601M |
| June 30, 2020 | 4.36M |
| March 31, 2020 | 6.954M |
| December 31, 2019 | 5.492M |
| September 30, 2019 | 6.084M |
| June 30, 2019 | 0.527M |
| March 31, 2019 | 0.4601M |
| December 31, 2018 | 0.3871M |
| September 30, 2018 | 0.3419M |
| June 30, 2018 | 0.3917M |
| March 31, 2018 | 0.4599M |
| December 31, 2017 | 0.122M |
| September 30, 2017 | 0.034M |
| Date | Value |
|---|---|
| June 30, 2017 | 0.0404M |
| March 31, 2017 | 0.0319M |
| December 31, 2016 | 0.0222M |
| September 30, 2016 | 0.0186M |
| June 30, 2016 | 0.0211M |
| March 31, 2016 | 0.0207M |
| December 31, 2015 | 0.0247M |
| September 30, 2015 | 0.0255M |
| June 30, 2015 | 0.031M |
| March 31, 2015 | 0.0209M |
| December 31, 2014 | 0.0227M |
| September 30, 2014 | 0.0247M |
| June 30, 2014 | 0.0261M |
| March 31, 2014 | 0.0393M |
| December 31, 2013 | 0.045M |
| September 30, 2013 | 0.0476M |
| June 30, 2013 | 0.0259M |
| March 31, 2013 | 0.0292M |
| December 31, 2012 | 0.0282M |
| September 30, 2012 | 0.025M |
| June 30, 2012 | 0.0328M |
| March 31, 2012 | 0.0252M |
| December 31, 2011 | 0.032M |
| September 30, 2011 | -0.426M |
| June 30, 2011 | 0.1978M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
0.527M
Minimum
Jun 2019
10.76M
Maximum
Jun 2023
5.378M
Average
5.546M
Median
Revenue (Quarterly) Benchmarks
| AIM ImmunoTech Inc | 0.065M |
| Perspective Therapeutics Inc | -5.239M |
| Protalix BioTherapeutics Inc | 3.748M |
| Electromed Inc | 13.87M |
| Armata Pharmaceuticals Inc | -- |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | 0.067M |
| Total Expenses (Quarterly) | 4.994M |
| EPS Diluted (Quarterly) | 0.0005 |
| Enterprise Value | 36.63M |
| Gross Profit Margin (Quarterly) | 95.74% |
| Profit Margin (Quarterly) | 1.34% |
| Earnings Yield | -89.52% |
| Operating Earnings Yield | 10.52% |
| Normalized Earnings Yield | -104.30 |